Natera (NTRA) Set to Release Quarterly Earnings on Thursday

Natera (NASDAQ:NTRA) is anticipated to release its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Natera to announce earnings of ($0.2812) per share and revenue of $707.54 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm had revenue of $752.75 million for the quarter, compared to the consensus estimate of $661.24 million. During the same quarter in the prior year, the firm posted ($0.74) earnings per share. The business’s revenue was up 37.7% on a year-over-year basis. On average, analysts expect Natera to post ($1.14) EPS for the current fiscal year and ($0.10) EPS for the next fiscal year.

Natera Stock Up 2.6%

NASDAQ:NTRA opened at $388.63 on Wednesday. The stock has a market cap of $56.02 billion, a price-to-earnings ratio of -285.76 and a beta of 1.55. The company’s 50 day moving average price is $379.22 and its 200-day moving average price is $267.89. Natera has a 52 week low of $181.00 and a 52 week high of $437.41.

Key Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: New oncology data presented at ESMO may strengthen the case for Natera’s cancer-testing business and broaden investor interest in its growth prospects. Natera stock: ESMO data broaden the oncology case
• Positive Sentiment: Analysts’ consensus price target is $394.31, slightly above the $388.63 reference opening price, and the consensus rating is “Moderate Buy.” That suggests modest potential upside, though the target is not a guarantee. Natera consensus target price
• Neutral Sentiment: Natera is due to report earnings November 5. The results and outlook could be a near-term catalyst, but the available preview does not provide specific forecasts. Natera to report earnings
• Neutral Sentiment: CFO Michael Brophy sold 1,178 shares under a pre-arranged Rule 10b5-1 plan and retained 48,480 shares. The planned nature and limited size of the sale may temper its significance as a signal about management’s outlook. CFO share sale
• Negative Sentiment: Recent coverage reported steep share declines, including drops of 6.5% and 8.4% in separate accounts. The headlines do not identify a definitive cause, but the pullback highlights volatility and risk ahead of earnings. Natera after-hours decline

Insider Activity at Natera

In related news, CEO Steven Chapman sold 3,430 shares of the firm’s stock in a transaction that occurred on Wednesday, October 28th. The shares were sold at an average price of $426.34, for a total value of $1,462,346.20. Following the sale, the chief executive officer owned 91,232 shares in the company, valued at approximately $38,895,850.88. This trade represents a 3.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Fesko sold 6,517 shares of Natera stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $321.53, for a total transaction of $2,095,411.01. Following the completion of the sale, the insider directly owned 197,257 shares of the company’s stock, valued at approximately $63,424,043.21. This trade represents a 3.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 45,256 shares of company stock valued at $16,455,344 over the last ninety days. Company insiders own 5.05% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. BTIG Research upped their price objective on Natera from $320.00 to $430.00 and gave the company a “buy” rating in a research report on Tuesday, October 27th. Citigroup lifted their target price on Natera from $365.00 to $480.00 and gave the stock a “buy” rating in a report on Tuesday, October 6th. Royal Bank Of Canada lifted their target price on Natera from $350.00 to $460.00 and gave the stock an “outperform” rating in a report on Friday, September 25th. Canaccord Genuity Group boosted their price target on Natera from $375.00 to $500.00 and gave the stock a “buy” rating in a research note on Monday, October 19th. Finally, Leerink Partners set a $330.00 price target on Natera in a report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $394.31.

About Natera

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.